市場調查報告書
商品編碼
1355818
雙歧桿菌市場規模 - 按產品類型(長雙歧桿菌、短雙歧桿菌、嬰兒雙歧桿菌、動物雙歧桿菌、乳雙歧桿菌)、應用、最終用途、配銷通路和全球預測,2023 - 2032Bifidobacterium Market Size - By Product Type (Bifidobacterium Longum, Bifidobacterium Breve, Bifidobacterium Infantis, Bifidobacterium Animalis, Bifidobacterium Lactis), Application, End Use, Distribution Channel & Global Forecast, 2023 - 2032 |
在對眾多健康益處的持續研究的推動下,雙歧桿菌市場規模從 2023 年到 2032 年的複合年成長率預計將達到 8%。
多項科學研究揭示了雙歧桿菌對腸道健康、免疫功能和整體健康的正面影響。因此,消費者擴大尋求含有雙歧桿菌的產品來解決消化問題、增強免疫力並主動支持健康。越來越多的研究不僅增強了消費者的信心,還鼓勵創新和新配方的開發,以擴大基於雙歧桿菌的產品的可用性和應用。
雙歧桿菌市場根據產品類型、應用、最終用途、配銷通路和地區進行分類。
就產品類型而言,預計到2032 年,動物雙歧桿菌細分市場的市場規模將獲得顯著成長。這種成長可歸因於動物雙歧桿菌作為益生菌菌株的重要性日益增加,因為它們具有潛在的健康益處,特別是在支持消化健康和免疫。 2022 年 6 月發表的一項研究發現,補充動物雙歧桿菌亞種。乳酸(Bifal)和精胺酸(Arg)可以顯著提高人類認知能力,尤其是老年人。為此,消費者擴大尋求含有動物雙歧桿菌的產品,以改善腸道微生物群和整體健康。
根據應用情況,製藥領域的雙歧桿菌產業將在 2023 年至 2032 年實現強勁成長。雙歧桿菌菌株擴大用於醫藥產品,特別是益生菌補充劑和用於解決各種健康狀況的藥物。最近,製藥公司正在將有益的益生菌涵蓋配方中,因為它們具有增強整體健康和福祉的潛力。製藥業益生菌研發投資的激增以及對基於益生菌的製藥解決方案的需求不斷成長將促進該領域的成長。
從區域來看,由於人們對健康和保健的高度重視,以及人們對腸道健康重要性和益生菌作用的認知不斷增強,到 2032 年,歐洲雙歧桿菌市場將大幅成長。該地區消費者對益生菌產品的需求較高,包括乳製品、補充劑和含有雙歧桿菌菌株的功能性食品。此外,有利的監管框架和指導方針將支持市場成長。
Bifidobacterium Market size is poised to 8% CAGR from 2023 to 2032, propelled by continuous research for numerous health benefits.
Several scientific studies have revealed the positive impacts of bifidobacterium on gut health, immune function, and overall well-being. As a result, consumers are increasingly seeking products containing bifidobacterium to address digestive issues, boost immunity, and support health proactively. The growing body of research is not only fostering consumer confidence but also encouraging innovations and the development of new formulations for expanding the availability and application of bifidobacterium-based products.
The bifidobacterium market is categorized based on product type, application, end use, distribution channel, and region.
With respect to product type, the market size from the bifidobacterium animalis segment is projected to gain significant traction through 2032. The growth can be attributed to the rising importance of bifidobacterium animalis as probiotic strains for their potential health benefits, particularly in supporting digestive health and immunity. A study published in June 2022 found that supplementing with Bifidobacterium animalis subsp. lactis (Bifal) and arginine (Arg) could significantly boost human cognition, particularly in older adults. To that end, consumers are increasingly seeking products containing bifidobacterium animalis to improve gut microbiome and overall well-being.
Based on application, the bifidobacterium industry from the pharmaceutical segment will record robust growth from 2023-2032. Bifidobacterium strains are increasingly utilized in pharmaceutical products, particularly in probiotic supplements and medications for addressing various health conditions. Lately, pharmaceutical companies are incorporating beneficial probiotics into formulations due to their potential to enhance overall health and well-being. The surging number of probiotic R&D investments in the pharmaceutical industry along with the growing demand for probiotic-based pharmaceutical solutions will add to the segment growth.
Regional, the bifidobacterium market in Europe will witness considerable growth up to 2032 due to the strong emphasis on health and wellness along with the growing awareness of the importance of gut health and the role of probiotics. There has been higher consumer demand for probiotic products, including dairy, supplements, and functional foods containing Bifidobacterium strains in the region. Additionally, favorable regulatory frameworks and guidelines will support the market growth.